BioPharm International-01-02-2011

The role of TLR agonists has expanded, and now the molecules can be found in a variety of non-vaccine therapeutics.


January 02, 2011

The global head of technical operations at Novartis talks about new technologies for vaccine development and manufacturing.

Safety concerns remain for developing replicating vectors based on the pathogen human immunodeficiency virus type 1.

Virosomes present novel drug-delivery vehicles with distinct advantages over liposomes.